ABBV News

AbbVie's (NYSE:ABBV) short percent of float has fallen 13.51% since its last report. The company recently reported that it has 11.38 million shares sold short, which is 0.64% of all regular shares that are available for trading.

President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."  The President underscored his goal to cut the cancer death rate in the U.S. by at least 50% over the next 25 years.

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

If history is any guide, there may be trouble ahead for shares of AbbVie (NYSE:ABBV). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 16 strange trades.

On CNBC’s “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management said that AbbVie Inc (NYSE: ABBV) has “come down from 175.” “It&rsqu

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners.

The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE: ABBV) RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) .

Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS.

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 30 strange trades.

Here's a roundup of top developments in the biotech space over the last 24 hours.

AbbVie (NYSE:ABBV) reported its Q1 earnings results on Friday, April 29, 2022 at 07:44 AM. Here's what investors need to know about the announcement.

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 6.18% on an annualized basis producing an average annual return of 18.59%. Currently, AbbVie has a market capitalization of $275.98 billion.

AbbVie (NYSE:ABBV) is set to give its latest quarterly earnings report on Friday, 2022-04-29. Here's what investors need to know before the announcement. Analysts estimate that AbbVie will report an earnings per share (EPS) of $3.14.

Here's a roundup of top developments in the biotech space over the last 24 hours: